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Abstract: The objective of this study was to evaluate the usefulness of a hydroalcoholic extract
from Galinsoga parviflora herb (GP) in some aspects of the endothelial cell function necessary for
anti-inflammatory activity and wound healing and relate these to the GP phytochemical profile.
This study demonstrated that the GP extract caused a dose-dependent reduction of IL-6 secretion
on IL-1β-stimulated endothelial cells. The IL-6 release was decreased to 33% ± 9% while this
did not influence the IL-6 secretion without stimulation. Additionally, the GP extract exhibited
an anti-hyaluronidase activity (IC50 = 0.47 mg/mL), which was evidently stronger than the positive
control kaempferol (IC50 = 0.78 mg/mL) as well as a moderate and concentration-dependent,
antioxidant activity. The results of the scratch assay showed that exposure of the endothelial cells to
GP induced complete healing of the damage after 12 h of the study. The phytochemical profile of
the extract was studied by using spectrophotometric (total amount of polyphenols and flavonoids)
and UPLC (phenolic acids) methods. The main compound in the GP extract was a chlorogenic acid
(2.00 ± 0.01 mg/g by UPLC). The total content of polyphenols was 98.30 ± 0.14 mg of chlorogenic
acid equivalent/g of the dry herb and content of flavonoids amounted to 6.15 ± 0.41 mg quercetin
equivalent/g of the dry herb. Moreover, the presence of flavonoids in G. parviflora was provided
after their isolation and identification by spectroscopic methods. In conclusion, it demonstrated
that application of GP in the treatment of skin lesions gives possibility of wound healing based on
antioxidant, anti-inflammatory, and hyaluronidase-inhibiting activities of G. parviflora herb extract.
Keywords: gallant soldier; polyphenols; anti-inflammatory; antioxidant; anti-hyaluronidase activity;
endothelium; IL-6
1. Introduction
Inflammation is a key protective response to tissue injury. If uncontrolled, however, it can
produce some collateral damage and contribute to further tissue destruction. The inflammatory
reaction is regulated at many levels by cytokines, eicosanoids, adhesion molecules, reactive oxygen,
and nitrogen species. Pharmacological attempts to curtail inflammation include cytokine inhibitors,
soluble receptors or antagonists, antioxidants, and pro-resolving mediators.
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Many medicinal plants used successfully in folk medicine display anti-inflammatory properties,
albeit the exact molecular mechanisms by which they produce these beneficial effects are often poorly
defined. It was proven that they cause transcriptional or post-transcriptional control of gene expression,
inhibition of pro-inflammatory cytokines and eicosanoids, and/or antioxidant activity [1].
The gallant soldier (Galinsoga parviflora Cav.) (GP) is a cosmopolitan annual herb from the
Asteraceae family. Fresh leaves and juice of GP have been used in folk medicine throughout the world to
treat dermatological disorders including eczema, lichen, and non-healing and/or bleeding wounds [2].
Less often GP is administered orally to cure the common cold, the flu, and cold sores. GP has been also
used as an anti-scurvy agent due to the high level of vitamin C. Moreover, GP can reduce the activation
of an inflammatory response and possesses analgesic properties. The aqueous extracts of aerial parts
of GP have protective effects against UV irradiation damages [2–5]. The extracts of the aerial part
of GP have been found to exert significant antibacterial, antifungal [6], and antiviral activities [7].
In turn, essential oil from GP can inhibit the growth of S. aureus and B. cereus [8]. Various chemical
compounds and extracts of gallant soldier have shown α-glucosidase, hepato-protective, nematicidal,
and hypoglycemic activities. The use of GP as food by humans for making salad and soups in Latin
and North America proves that the plant is non-toxic [2–5].
The aim of the present study was to examine anti-inflammatory, anti-hyaluronidase, and anti-
antioxidant activity of hydroalcoholic extract of GP and to evaluate the healing process (in vitro) in regards
to the GP phytochemical profile.
2. Results
2.1. Phytochemical Analysis and Quantification of the Major Compounds
2.1.1. Isolation of Flavonoids
In the current study, seven known flavonoids were isolated from the ethyl acetate and water
extracts of the GP herb by using cellulose column chromatography. Their structures were identified
based on spectroscopic analyses (1H-NMR, 13C-NMR, and/or ESI-MS) in comparison with the
literature [9,10] (see Supplementary Materials).
2.1.2. UPLC Analysis of GP Extract
The identification and the quantification of phenolic acids were carried out by means of
an ultra-high performance liquid chromatography supported by a photodiode array detector.
The chromatograms were evaluated for linearity, limits of quantification, and recovery of each of the
phenolic acids under study (Table 1).
Table 1. Regression data, LODs, LOQs, and recovery for studied compounds.
Phenolic Acid Regression Equation R2
Linear Range
(µg/mL)
LOD
(µg/mL)
LOQ
(µg/mL)
Recovery
(%)
gallic y = 88,398x − 53,935 0.9999 5–40 0.45 1.34 71.74 ± 0.02
protocatechuic y = 104,765x − 45,841 0.9999 5–40 0.25 0.75 90.03 ± 0.05
chlorogenic y = 79,806x − 60,132 0.9998 5–40 0.74 2.22 83.63 ± 0.01
4-hydroxybenzoic y = 184,507x − 6297 0.9994 5–40 0.75 2.24 90.61 ± 0.07
caffeic y = 145,745x − 104,383 0.9995 5–40 0.63 1.89 84.42 ± 0.05
isovanilic y = 112,849x − 67,266 0.9999 5–40 0.25 0.76 90.39 ± 0.06
The UPLC analysis of the hydroalcoholic GP extracts demonstrated the presence of protocatechuic,
chlorogenic, 4-hydroxybenzoic, caffeic, and isovanilic acids (Figure 1). The highest content was
determined for chlorogenic acid (2.00 ± 0.01 mg/g of the dry herb). The other phenolic acids occurred
in the lower amounts (µg/g of the dry herb): protocatechuic acid (200.32 ± 4.3), 4-hydroxybenzoic
acid (100.43 ± 0.2), caffeic acid (120.54 ± 2.8), and isovanilic acid (60.38 ± 1.6).
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Figure 1. SPE-UPLC fingerprint of the G. parviflora extract (GP).
2.1.3. Total Phenolic and Flavonoid Content
Total phenolic content (TPC) and total flavonoid (TFC) content of the GP extract were 98.30± 0.14 mg
chlorogenic acid equivalent/g of the dry herb and 6.15 ± 0.41 mg/quercetin equivalent/g of the dry
herb, respectively.
2.2. Bioactivity Assay
2.2.1. LAL Assay
concentration of endotoxins of <0.01 ng/mL in GP extract was considered acceptable and this
extract as used for further in vitro studies. The concentration of GP as <1.0 g/mL.
2.2.2. Viability and Proliferati ss
Exposure of e othelial cells t t t i mL did not i pair ce l
viability the trypan blue exclusion test (Figure 2A). The GP extract at a dose of
0.5 mg/mL also lightly stimulated endothelial cel proliferation. However, th growth of cells treated
with the GP concentration a twice s high an amount did not have a y signific t effect (Figur 2B).
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Figure 2. Effect of the G. parviflora extract (GP) on endothelial cell viability (A) and proliferation (B).
Cells were treated with the GP extract or vehicle control for 24 h and was then assessed for viability
(Trypan blue exclusion test) and proliferation (MTT test). The data were derived from three independent
experiments. The data expressed as mean ± SD. Asterisks represent a significant difference compared
to control cells (* p < 0.05).
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2.2.3. Cytokine Measurements
None of the tested concentrations of the GP extract changed constitutive IL-6 release by endothelial
cells (Figure 3A). In contrast, the exposure to the GP resulted in a dose-dependent decrease in
IL-1β-stimulated IL-6 secretion (Figure 3B). The highest concentration of the GP caused the release of
Il-1β-stimulated IL-6, which was reduced to 33% ± 9%.
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Figure 3. Effect of G. parviflora extract (GP) on IL-6 release by endothelial cells. Cells were treated with
a GP extract in the absence (A) or presence (B) of Il-1β (1 ng/mL) for 24 h. The data were derived
from four independent experiments and are expressed as a parentage of control (mean ± SD). The IL-6
release was detected as pg/µg cell protein. Asterisks represent a significant difference when compared
to control cells (* p < 0.5).
2.2.4. Anti-Hyaluronidase Activity
The results of an anti-hyaluronidase activity assay are shown in Figure 4. The study showed that
the GP xtract (IC50 = 0.47 mg/mL) exhibited a stronger activity than the positive control kaempferol
(IC50 = 0.78 mg/mL).
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Figure 4. Anti-hyaluronidase activity of G. parviflora extract (GP) and the reference substance. Results
are presented as mean values ± SD (n = 3 × 2) represented by error bars, IC50, 50% inhibition of
enzyme activity.
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2.2.5. Antioxidant Activity
The FRAP assay revealed a potent antioxidant property of the GP extract with estimated
IC0.5 = 498.2 µg/mL of the dry herb when compared to IC0.5 = 44.40 µg/mL for L-ascorbic acid.
2.2.6. Measurement of Reactive Oxygen Species (ROS)
The GP extract reduced dose-dependently ROS generation by endothelial cells. In cells treated
with the GP extract at 1.0 mg/mL, the level of intracellular ROS was decreased by approximately 30%.
The effect of the GP extract was clearly seen in cells labeled independently with two different dyes
H2DCFDA and DHR using an in vitro culture (Figure 5A,B). Doing experiments with DCFDA labeling
in vitro, we use as the positive control H2O2. The ROS production in response to hydrogen peroxide
was 196% ± 7% when compared with control cells. The reaction to H2O2 is usually between 80% to
150% higher than that observed in the control cell HUVEC line EA.hy926 (personal observation).
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3. iscussion
atural substances are often used for the treat ent of skin infla ation and ound healing.
ne of the plants used for this purpose in folk edicine is G. parviflora. In our study, e verified
hether the use of hydroalcoholic extract fro this plant species has a scientific justification.
efining the chemical profiles of plant extracts can justify their biological activity. Phytochemical
studies of G. parviflora confirmed the presence of several phenolic compounds with potential
biological activity.
Fro aerial parts of G. parviflora used to prepare the hydroalcoholic extract for the bioactivity assay,
we isolated seven flavonoids and identified them by ESI-MS, 1H, and 13C-NMR as miquelianin, isoquercitrin,
rutin, astragalin, quercimeritrin, quercetagetrin, and patulitrin. As a result of the previous LC-MS analysis
of the GP extract, the different flavones, flavonols, and flavanones were also detected [2,11–14].
Our UPLC study of the hydroalcoholic GP extract revealed the presence of five phenolic acids.
Apart from the protocatechuic, chlorogenic, 4-hydroxybenzoic, and caffeic, which were found in the
previous studies [15–17]. We additionally detected the presence of isovanilic but not caffeoylglucaric
acids [17]. Our results showed that chlorogenic acid is the major constituent from the group of phenolic
acids in the GP extract and its total concentration was 2.00 ± 0.01 mg/g of the dry herb. The content
of protocatechuic, 4-hydroxybenzoic, caffeic, and isovanilic acids amounts to (µg/g of the dry herb)
200.32 ± 4.3, 100.43 ± 0.2, 120.54 ± 2.8, and 60.38 ± 1.6, respectively. The chlorogenic acid content
detected in our GP extract was comparable with the one previously determined by Ranilla et al. [16].
The analysis of the content of total polyphenols showed their high quantity in our hydroalcoholic
extract. The similar analysis of methanolic and aqueous extracts from G. parviflora, which contained
15.3 and 24.1 mg gallic acid/g of dry herb, respectively, which was performed by Akula et al. [18].
Despite the Akula studies, the content was expressed as equivalent of gallic acid. We can affirm that
the hydroalcoholic extract is a preparation rich in polyphenolic compounds. The obtained results
of total flavonoids indicate their moderate content in the examined GP extract. Our res lts of the
phytochemical analysis the GP extract provide more detailed information about flavonoid and phenolic
acid profiles of this plant species.
The next step of our study was the evaluation of the biological properties of GP extract, which are
important in supporting the treatment of inflammation. Inflammation is a multifactorial and multistage
process that is accom anied by various factors such as the high level of interleukin production a
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increased hyaluronidase activity [19]. It is obvious that excessive hyaluronidase activity causes
vasodilatation, boosts permeability, and, as a consequence, local redness and edema.
In the present study, we showed for the first time that the GP extract caused a dose-dependent
reduction of IL-6 secretion on IL-1β-stimulated endothelial cells and the release was significantly decreased
in both of the studied concentrations (Figure 3). The previous study showed that ethanolic GP extracts
inhibit the arachidonic acid inflammatory pathway by blocking the activity of cyclooxygenase (COX-1) [20]
and lipoxygenase (5-LOX) [18]. Moreover, GP can reduce the activation of the inflammatory response [21].
Several in vitro and in vivo models have clearly demonstrated anti-inflammatory activity of several
phenolics such as chlorogenic acid, rutin, and quercetin 3-O-β-glucuronide, which are also present in
the GP extract examined in our study [22–24]. The activity of these compounds resulted in decreasing the
secretion of pro-inflammatory cytokines IL-6 in cells stimulated with TNF-α, LPS, and IL-1β. Therefore,
it can be assumed that these GP ingredients are responsible for the anti-inflammatory effect [25,26].
Our study revealed that the GP extract completely inhibited the hyaluronidase activity at the
concentration of 2.50 mg/mL (Figure 4). It has been shown that the hyaluronidase inhibitory activity
is characteristic for quercetin derivatives (rutin and quercetin 3-O-β-glucuronide) and it is higher than
that of the phenolic acids (chlorogenic and protocatechuic) [27–29]. The presence of rutin and the high
content of phenolic compounds especially chlorogenic acid in hydroalcoholic GP extract can justify the
anti-hyaluronidase activity.
Inflammation is also associated with the generation of large amounts of free radicals. Oxidative
stress is capable of activating transcription factors (e.g., NF-κB) that promote the synthesis of
pro-inflammatory cytokines (e.g., IL-6). In this respect, it has been demonstrated that antioxidants can
reduce IL-6 and TNF-α by macrophages [30] and inhibit cyclooxygenase-2 and inducible nitric oxide
synthase expression [31] as well as enhance anti-inflammatory IL-10 secretion [30]. In order to evaluate
the antioxidant activity of polyphenol-rich GP extract, two used in in vitro models were applied. In our
study the GP extract exhibited a moderate concentration-dependent antioxidant activity. The activity
analyzed by using a FRAP assay was 11 times lower in comparison with vitamin C. The antioxidant
properties of the GP extract were also confirmed by measuring ROS production by endothelial cell
using DHR and DCFDA. The data demonstrated a wide spectrum of activity of the examined extract
on ROS concentration in cells.
An interesting antioxidant activity of different GP extracts was also documented in other authors’
research. The study by Bazylko et al. [17] involved the scavenging of two radicals (O2•− and H2O2)
generated by fibroblasts in cell-free systems and in human skin after UV irradiation by methanolic and
aqueous GP extracts. Previous studies have also indicated that GP inhibits linoleic acid oxidation and is
capable of scavenging ROS [11,16,18]. Chanaj-Kaczmarek and coworkers detected a potent antioxidant
activity with value IC50 = 47.21 µg/mL and IC50 = 66.38 µg/mL for decoction and 70% methanolic
extract, respectively, using the ABTS assay. Additionally, the antioxidant activity was tested using
a method of the Saccharomyces cerevisiae yeast strain without gene sod1. The decoction and 70% extract
improved the viability of S. cerevisiae due to antioxidative activity of phenolic compounds especially
phenolic acids [32]. The antioxidant properties of GP proven in our analysis as well as in the other
research studies suggest that this plant species may exert a beneficial effect in the symptoms associated
with inflammation.
Many reports have demonstrated that flavonoids (e.g., kaempferol, quercetin) support the
acceleration of wound closure through a complex mechanism that involves inducing intercellular
calcium-dependent pathways, stimulating collagen deposition, and suppressing cyclooxygenase-2
(COX-2) expression [33,34]. In the case of chlorogenic acid, a significant acceleration of keratinocyte
wound closure as measured by a scratch assay has been demonstrated [35]. Moreover, a study
conducted by Schmidt showed that hexane and ethanol extracts of GP promote migration and
proliferation of fibroblasts and thus facilitate wound healing [21]. The results of these studies have not
been confirmed in our research.
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Our study, which was carried out on endothelial cells, showed that the hydroalcoholic GP extract
slightly enhanced the proliferation process. Despite the high content of chlorogenic acid and the
presence of flavonoids in GP extract, the improvement of wound closure was observed only after eight
and 10 hours. However, the results in the scratch assay were not statistically significant.
4. Material and Methods
4.1. Chemicals and Instruments
Aluminium trichloride, formic acid, hydrochloric acid, sodium carbonate, sodium hydroxide,
DMSO, and solvents used for extraction and separation flavonoids were purchased from Avantor
Performance Materials Poland S.A. (Gliwice, Poland). The Folin-Ciocalteu′s phenol reagent was from
Merck (Darmstadt, Germany), HPLC grade water, HPLC grade acetonitrile, acetate buffer were from
the JT Baker–Avantor Performance Materials B.V. (Deventer, The Netherlands), and chlorogenic acid
and kaempferol from Roth GmbH (Karlsruhe, Germany). The lysis buffer was from Promega, (Madison,
WI, USA). The Protein Assay Dye Reagent was purchased from Bio-Rad (Hercules, CA, USA).
The Limulus amebocyte lysate (LAL) assay was from Thermo Fisher Scientific (Rockford, IL, USA).
All other chemicals were from the Sigma–Aldrich Chemical Co. (Taufkirchen, Germany). The cell
culture plastics were from Nunc (Roskide, Denmark).
CF-11 cellulose (Whatman Ltd., Maidstone, Kent, UK) and Sephadex LH-20 (25–100 µ) (Sigma–Aldrich
Chemical Co.) were used for column chromatography (CC). Preparative paper chromatography (PPC)
(Whatman paper No. 3 MM, Whatman Ltd. Maidstone, Kent, UK) was used to separated fractions obtained
after CC. Thin-layer chromatography (TLC) was performed on cellulose precoated plates (TLC Cellulose
25 Aluminium sheets 20× 20, Merck, Darmstadt, Germany). The chromatograms were visualized under
UV light at 366 nm before and after spraying with 0.1% methanolic Naturstoffreagenz A (Roth -Carl Roth
GmbH + Co., Karlsruhe, Germany).
1H-NMR and 13C-NMR spectra were measured on Varian 300 MHz (compounds 2–4), Bruker
Avance II 400 MHz (compounds 3,5) and Bruker Avance III 500 MHz (compounds 6,7). Chemical shifts
are given in ppm with tetramethylsilane (TMS) as an internal standard using DMSO-d6 or CD3-OD
as solvents. The ESI-MS spectra were obtained using a Waters/Micromass (Manchester, UK) ZQ
Mass spectrometer connected with HPLC (Waters typ 2690; Milford, CT, USA) and spectrometer UV
Photodiode Array Detector Waters 996 (λ = 200–500 nm). ESI-MS analyses for compounds 1–7 were
performed in positive and negative ionization models.
4.2. Plant Material
GP was collected (June, 2016) from the garden of the Department of Medicinal and Cosmetic
Natural Products, Poznan University of Medical Sciences and dried at room temperature. The voucher
specimen (No Gp-2016) was deposited at the Department of Pharmacognosy, Poznan University of
Medical Sciences.
4.3. Extracts Preparation
The herb of GP (5.0 g) was extracted with 50% methanol (two times at 250 mL) for 20 min at 95 ◦C
on a water bath. The extract was concentrated under a vacuum at 40 ◦C until it dries. The residue
obtained was diluted with 50 mL of water to yield a stock solution (0.1 g dry herb/mL) that was used
in further experiments. Final concentrations of the GP extract used are expressed as mg of dry herb
per mL.
An extract for flavonoid isolation (from 1000 g) was prepared in the same way.
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4.4. Phytochemical Analysis and Quantification of the Major Compounds
4.4.1. Isolation of the Flavonoids
The obtained dry extract was treated with hot distilled water. Water extract was extracted
successively with CHCl3 and then with Et2O and EtOAc. The ethyl acetate and water extracts were
fractionated on a cellulose column (CC) with EtOAc-MeOH-H2O (100:6:20, v/v/v) as an eluent to
obtain four (I, II, III, IV) and two fractions (V, VI) respectively. The fractions were collected and
combined by thin layer chromatography (TLC) examination using HOAC-H2O (15:85, v/v) and
n-BuOH-HOAc-H2O (6:1:2, v/v/v) as developing solvents. Compound 1 (13 mg) was isolated
from fraction IV by preparative paper chromatography (PPC) using n-BuOH-HOAc-H2O (6:1:2,
v/v/v). Fraction II and III were separated into compounds 2 (8 mg) and 3 (7 mg) by PPC using
HOAC-H2O (30:70, v/v). Compounds 4 (8 mg) and 5 (7 mg) were isolated from fraction V by
applying a cellulose column eluted by H2O. From the I fraction, compound 6 (13 mg) and 7 (9 mg)
were isolated by using twice PPC and HOAC-H2O (15:85, v/v) as an eluent. All the individual
compounds were re-chromatographed by CC on Sephadex LH-20 using MeOH-CHCl3 mixture (1:9,
v/v) for elution and identified using spectroscopic analysis. Their structures were identified based on
spectroscopic analyses (1H-NMR, 13C-NMR, and/or ESI-MS) in comparison with the literature [9,10]
(see Supplementary Materials).
Compound 1 (7-O-β-glucoside of quercetagetin = quercetagetrin): ESI-MS negative: m/z 479 [M − H]−,
m/z 317 [A − H]−; ESI-MS positive: m/z 481 [M + H]+, m/z 319 [A + H]+.
Compound 2 (quercetin 7-O-β-glucoside = quercimeritrin): ESI-MS negative: m/z 463 [M − H]−, m/z
301 [A − H]−; ESI-MS positive: m/z 465 [M + H]+, m/z 303 [A + H]+.1H-NMR (DMSO-d6) δ (ppm):
6.41 (d, J = 2.0 Hz, H-6), 6.76 (d, J = 2.0 Hz, H-8), 7.72 (d, J = 2.0 Hz, H-2′), 6.89 (d, J = 8.5 Hz, H-5′),
7.55 (dd, J = 2.0 and J = 8.6 Hz, H-6′), 5.07 (d, J = 7.2 Hz, H-1′ ′ glucose), 13C-NMR (DMSO-d6) δ (ppm):
147.90 (C-2), 136.09 (C-3), 176.01 (C-4), 160.34 (C-5), 98.73 (C-6), 162.66 (C-7), 94.23 (C-8), 155.71 (C-9),
104.64 (C-10), 121.80 (C-1′), 115.56 (C-2′), 145.05 (C-3′), 147.56 (C-4′), 115.34 (C-5′), 120.02 (C-6′), 99.85
(C-1′ ′), 73.10 (C-2′ ′), 77.13 (C-3′ ′), 69.53 (C-4′ ′), 76.38 (C-5′ ′), 60.59 (C-6′ ′).
Compound 3 (patuletin-7-O-β-glucopyranoside = patulitrin): ESI-MS negative: m/z 493 [M − H]−,
m/z 331 [A − H]−, ESI-MS positive: m/z 495 [M + H]+, m/z 333 [A + H]+.1H-NMR (CD3-OD) δ (ppm):
6.88 (s, H-8), 7.76 (d, J = 1.6 Hz, H-2′), 6.88 (d, J = 8.7 Hz, H-5′), 7.67 (dd, J = 1.8 and J = 8.2 Hz, H-6′),
3.92 (s, OCH3), 5.10 (d, J = 7.3 Hz, H-1′ ′ glucose), 13C-NMR (DMSO-d6) δ (ppm): 147.69 (C-2), 135.80
(C-3), 176.13 (C-4), 151.04 (C-5), 131.80 (C-6), 156.36 (C-7), 93.84 (C-8), 151.39 (C-9), 104.96 (C-10), 121.84
(C-1′), 115.41 (C-2′), 145.06 (C-3′), 147.91 (C-4′), 115.58 (C-5′), 120.03 (C-6′), 60.32 (OCH3), 100.13 (C-1′ ′),
73.20 (C-2′ ′), 76.68 (C-3′ ′), 69.56 (C-4′ ′), 77.22 (C-5′ ′), 60.60 (C-6′ ′).
Compound 4 (quercetin-3-O-β-glucopyranoside = isoquercitrin): ESI-MS negative: m/z 463 [M − H]−,
m/z 301 [A − H]−, ESI-MS positive: m/z 465 [M + H]+, m/z 303 [A + H]+.1H-NMR (DMSO-d6) δ
(ppm): 12.64 (s, 5-OH), 6.19 (d, J = 1.9 Hz, H-6), 6.40 (d, J = 1.9 Hz, H-8), 7.57 (d, J = 2.0 Hz, H-2′), 6.84
(d, J = 9.0 Hz, H-5′), 7.57 (dd, J = 2.2 and J = 8.9 Hz, H-6′), 5.46 (d, J = 7.5 Hz, H-1′ ′ glucose), 13C-NMR
(DMSO-d6) δ (ppm): 156.12 (C-2), 133.29 (C-3), 177.40 (C-4), 161.21 (C-5), 98.68 (C-6), 164.26 (C-7), 93.51
(C-8), 156.31 (C-9), 103.90 (C-10), 121.12 (C-1′), 115.20 (C-2′), 144.81 (C-3′), 148.47 (C-4′), 116.16 (C-5′),
121.58 (C-6′), 100.85 (C-1′ ′), 74.08 (C-2′ ′), 76.49(C-3′ ′), 69.91 (C-4′ ′), 77.55 (C-5′ ′), 60.94 (C-6′ ′).
Compound 5 (quercetin-3-O-β-glucuronide = miquelianin): ESI-MS negative: m/z 477 [M − H]−, m/z
301 [A − H]−; ESI-MS positive: m/z 479 [M + H]+, m/z 303 [A + H]+.1H-NMR (DMSO-d6) δ (ppm):
12.26 (s, 5-OH), 6.17 (d, J = 1.9 Hz, H-6), 6.36 (d, J = 1.9 Hz, H-8), 8.28 (d, J = 2.2 Hz, H-2′), 6.82 (d,
J = 8.4 Hz, H-5′), 7.34 (dd, J = 2.0 and J = 8.4 Hz, H-6′), 5.20 (d, J = 7.4 Hz, H-1′ ′ glucuronic acid), 3.38
(d, J = 9.2, H-5′ ′ glucuronic acid), 13C-NMR (DMSO-d6) δ (ppm): 157.61 (C-2), 134.05 (C-3), 177.57 (C-4),
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160.92 (C-5), 98.95 (C-6), 164.92 (C-7), 93.78 (C-8), 156.50 (C-9), 103.55 (C-10), 120.61 (C-1′), 118.02 (C-2′),
144.79 (C-3′), 148.42 (C-4′), 115.40 (C-5′), 120.45 (C-6′), 103.08 (C-1′ ′), 73.95 (C-2′ ′), 76.63 (C-3′ ′), 71.78
(C-4′ ′), 74.16 (C-5′ ′), 172.20 (C-6′ ′).
Compound 6 (kaempferol-3-O-β-glucopyranoside = astragalin): ESI-MS negative: m/z 447 [M − H]−,
m/z 285 [A − H]−, ESI-MS positive: m/z 449 [M + H]+, m/z 287 [A + H]+.1H-NMR (DMSO-d6) δ
(ppm): 12.61 (s, 5-OH), 6.21 (d, J = 1.6 Hz, H-6), 6.43 (d, J = 1.6 Hz, H-8), 8.04 (d, J = 8.7 Hz, H-2′and
H-6′), 6.88 (d, J = 8.7 Hz, H-3′and H-5′), 5.46 (d, J = 7,4 Hz, H-1′ ′ glucose); 13C-NMR (DMSO-d6) δ
(ppm): 156.23 (C-2), 133.16 (C-3), 177.46 (C-4), 161.21 (C-5), 98.67 (C-6), 164.12 (C-7), 93.63 (C-8), 156.36
(C-9), 103.99 (C-10), 120.88 (C-1′), 130.88 (C-2′), 115,09 (C-3′), 159.94 (C-4′), 115.09 (C-5′), 130.88 (C-6′),
100.82 (C-1′ ′), 74.20 (C-2′ ′), 77.49 (C-3′ ′), 69.87 (C-4′ ′), 76.40 (C-5′ ′), 60.81 (C-6′ ′).
Compound 7 (quercetin-3-O-α-rhamnopyranosylo (1→6)-β-glucopyranoside = rutin): ESI-MS negative:
m/z 609 [M−H]−, m/z 463 [M-rhamnosyl-H]¯, m/z 301 [A−H]−; ESI-MS positive: m/z 611 [M + H]+,
m/z 465 [M-rhamnosyl + H]+, m/z 303 [A + H]+. 1H-NMR (DMSO-d6) δ (ppm): 12.59 (s, 5-OH), 6.18
(d, J = 2.1 Hz, H-6), 6.37 (d, J = 2.1 Hz, H-8), 7.52 (d, J = 2.1 Hz, H-2′), 6.83 (d, J= 8.2 Hz, H-5′), 7.54
(dd, J = 2.2 and J = 8.3 Hz, H-6′), 5.34 (d, J = 7.5 Hz, H-1′ ′ glucose), 4.38 (d, J= 1.2 Hz, H-1′ ′ ′ rhamnose),
0.99 (d, J = 6.2 Hz, H-6′ ′ ′ rhamnose), 13C-NMR (DMSO-d6) δ (ppm):156.42 (C-2), 133.27 (C-3), 177.32
(C-4), 161.20 (C-5), 98.70 (C-6), 164.23 (C-7), 93.59 (C-8), 156.56 (C-9), 103.88 (C-10), 121.13 (C-1′), 115.20
(C-2′), 144.75 (C-3′), 148.43 (C-4′), 116.22 (C-5′), 121.57 (C-6′), 101.18 (C-1′ ′), 74.05 (C-2′ ′), 75.88 (C-3′ ′),
69.98 (C-4′ ′), 76.42 (C-5′ ′), 66.97 (C-6′ ′), 100.73 (C-1′ ′ ′), 70.35 (C-2′ ′ ′), 70.53 (C-3′ ′ ′), 71.82 (C-4′ ′ ′), 68.23
(C-5′ ′ ′), 17.72 (C-6′ ′ ′).
4.4.2. UPLC Analysis
Standard Solutions
The stock solutions (1 mg/mL) of phenolic acids: chlorogenic, caffeic, gallic, isovanilic,
4-hydroxybenzoic, and protocatechuic were freshly prepared in methanol. The working solutions were
prepared by diluting the stock solution using mobile phase A. 2.0 µL volume at each concentration
level of each phenolic acids working solutions (5–40 µg/mL) was injected eight times into the UPLC
system for the construction of the calibration curves.
Sample Preparation
The GP extract was added to the SPE process. The cartridge (Oasis HLB Plus Short Cartridge, Waters,
Milford, MA, USA) was conditioned with 5 mL of methanol followed by 5 mL of grade water. 1.0 mL of
the GP extract was eluted with 50 mL of 70% methanol. The organic eluate was collected in a flask and
then concentrated under the vacuum at 40◦C to dryness, diluted with mixture methanol-water (1:1, v/v)
to 2.0 mL, and then purified through a syringe filter (GHP, 25 mm, 0.2 µm, Waters).
Chromatographic Conditions
Identification and quantification of phenolic acids of GP extract were carried out by using
an ultra-high performance liquid chromatography (UPLC, Acquity, Waters). The method was
performed on an Acquity UPLC HSS T3 column (1.8 µm, 2.1 × 150 mm, Waters) with a guard
pre-column of Acquity UPLC BEH C18 (1.7 µm, 2.1 × 5 mm, Waters) at the column temperature of
24 ◦C. Elution was conducted using mobile phase A: HPLC grade water and mobile phase B: HPLC
grade acetonitrile. Each solvent (1000 mL) was acidulated by using formic acid (50 µL). The linear
gradient was as follows: 3% to 13% B over 0.0 to 4.0 min, 13% to 17.5% B over 4.0 to 5.0 min, 17.5% B
over 5.0 to 9.0 min, 17.5% to 3.0% B over 9.0 to 13.0 min with a flow rate of 0.275 mL/min. The spectral
data of signals from the PDA detector were collected during the whole run in the range of 234 to 330 nm
and processed by using Empower 2 Software Build 2154 (Waters, Milford, MA, USA). The presence
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of phenolic acids in the GP extract was confirmed by comparison of retention time and spectra of
particular substances.
Validation of the UPLC Method
Quantitative analyses of phenolic acids by the UPLC-PDA were validated with respect to linearity,
sensitivity, and precision. Linearity was evaluated by the correlation coefficient of the curves of studied
compounds. A limit of detection (LOD) and quantification (LOQ) were determined by the injection
of a series of dilutions of phenolic acids with LOD determined as the concentration that resulted in
a peak area three times greater than the noise level and LOQ is a concentration that resulted in a peak
area 10 times greater than the noise level. The precision of the method was estimated by running eight
injections of six different concentrations, which were given on the same day, and the values of relative
standard deviation were calculated to determine the intra-day precision.
4.4.3. Total Phenolic Content (TPC)
TPC was determined using the Folin–Ciocalteu method [36] with minor modifications. A total
of 0.2 mL of the extract (5 mg dry herb/mL) was mixed with 4.0 mL of water and 0.5 mL of
Folin–Ciocalteu′s reagent. After 1 min, 2.0 mL of 20% sodium carbonate aq. solution was added and
supplemented with distilled water to a total volume of 10 mL. The mixture was left for 30 min and
then its absorbance was measured at 760 nm in pentaplicate. A blank sample of water and reagents
was used as a reference. TPC was expressed as mg of chlorogenic acid equivalent per g of a dry herb
utilizing a calibration curve of chlorogenic acid (y = 4.8882x; R2 = 0.9954) in a concentration range
0.002 mg/mL to 0.012 mg/mL.
4.4.4. Total Flavonoid Content (TFC)
TFC was determined as described by Meda et al. [37]. Equal volumes of 2% AlCl3 in methanol the
GP extract (3 mg/mL) were mixed and left for 10 min. The absorbance was measured in pentaplicate
at 415 nm using a blank sample of water and methanol without AlCl3. TFC was expressed as mg of
quercetin (6.25–100 mg/mL) per 100 g of dry weight (y = 0.0383x + 0.0599; R2 = 0.9892).
4.5. Bioactivity Assay
4.5.1. FRAP Assay
The FRAP assay was performed according to Tiveron el al. [38] with some modifications. The stock
solutions of the FRAP reagent included 300 mM acetate buffer (pH 3.6), 10 mM TPTZ solution in
40 mM HCl, and 20 mM FeCl3·6H2O solution. The working FRAP solution was freshly prepared
by mixing 25 mL acetate buffer, 2.5 mL TPTZ solution, and 2.5 mL FeCl3·6H2O solution and then
warmed at 37 ◦C before usage. The examination of the GP extract (50 µL) was allowed to react with
the FRAP solution (1500 µL) at 37 ◦C for 30 min. in the dark condition. Then the absorbance was read
at 593 nm in pentaplicate. The standard curve was linear in the range of 10 to 100 µg Vitamin C/mL
with R2 = 0.9998. The results were expressed as the IC0.5 (µg/mL), which corresponded to the extract
concentration required to produce 0.5 O.D. value.
4.5.2. Anti-Hyaluronidase Activity
Inhibition of hyaluronidase (HA) by the GP extract was determined by a turbidimetric method
described by Grabowska et al. [39] with minor modifications. Additionally, 25 µL of enzyme (30 U/mL
of acetate buffer pH 7.0), 25 µL of acetate buffer (50 mM, pH 7.0, with 77 mM NaCl and 1 mg/mL
of albumin), 15 µL of acetate buffer (pH 4.5), and 10 µL solutions of the examined substances
(2.3–25 mg/mL) were combined in order to produce reagent mixtures with the final concentrations of
0.23 to 2.50 mg/mL. All the reaction mixtures were incubated at 37 ◦C for 10 min. Next, 25 µL of HA
(0.3 mg/mL of acetate buffer pH 4.5) was added and incubated at 37 ◦C for 45 min. The undigested HA
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was precipitated with the addition of 200 µL 2.5% CTAB in 2% NaOH (pH 12). The mixture was kept
at room temperature for 10 min. Turbidance of the reaction mixture was measured as the absorbance
at 600 nm (Multiskan GO 1510, Thermo Fisher Scientific, Vantaa, Finland). Kaempferol was used as
the positive control (final concentration 0.5–1.0 mg/mL). The absorbance in the absence of the enzyme
was used as the blind control. To exclude nonspecific changes in turbidity (caused by other factors
rather than not digested HA), the tests without HA solution were conducted. For the investigated
extract, three independent experiments were carried out in triplicate. The percentage of inhibition was
calculated by using the equation below.
% inhibition activity =
TS − TC
TH − Tc
·100% (1)
TS—absorbance of the enzyme + substrate (HA) + substance sample. TC—absorbance of the
enzyme + substrate (HA). TH—absorbance of the HA + substance sample.
4.5.3. Cell Culture
The experiments were performed using human umbilical vein endothelial cells (HUVECs) of the
EA.hy926 line (kindly donated by Dr. Edgell, University of North Carolina, Chapel Hill, NC, USA) [40].
Cells were routinely maintained in the Earl′s-buffered M199 culture medium, supplemented with
amphotericin (2.5 µg/mL), gentamycin (50 µg/mL), l-glutamine (2 mM), hydrocortisone (0.4 µg/mL),
and 10% v/v fetal calf serum (ThermoFisher Scientific, Waltham, Milford, MA, USA).
To ensure that the GP extract produced was not contaminated with endotoxin, GP extract was
tested with the Limulus amebocyte lysate (LAL) assay.
4.5.4. Cell Viability
The viability of cells treated with GP (0.125–1 mg/mL) was determined using the Trypan blue
exclusion test. Cells were suspended in Hanks′ Balanced Salt Solution and mixed 1:1 (v/v) with
0.4% Trypan blue solution. After 10 min, the number of blue-stained non-viable cells was counted in
a hemocytometer.
4.5.5. Cell Proliferation
Cell proliferation was measured using the MTT assay [41]. Following exposure to the GP extract,
cells were incubated for 4 h at 37 ◦C with 1.25 mg/mL MTT salt (3-[4.5-dimethylthiazol-2-yl]-
2.5-diphenyl-tetrazolium bromide). The formazan product generated was dissolved with acidic
solution of 20% w/v sodium dodecyl sulphate and 50% v/v N,N-dimethylformamide. The absorbance
of the converted dye was recorded at 595 nm with a reference wavelength of 690 nm.
4.5.6. Cytokine Measurements
Endothelial cells were exposed to GP extract (0.5–1 mg/mL) in the presence or absence of
IL-1β (1 ng/mL). After 24 h, the medium was collected and frozen at −80◦C until it was assayed.
The cells were lysed with 0.1 N NaOH and measured for protein concentration with the Bradford
method using the Protein Assay Dye Reagent. IL-6 concentrations were measured with the DuoSet
Immunoassay Development Kits (R&D Systems, Minneapolis, MN, USA) as per manufacturer′s
instructions. The sensitivity of the assay was estimated to be 2.6 pg/mL.
4.5.7. Wound Healing
The assay was performed as described previously [42,43]. The cells were grown to confluence
and then scratched with a cell scraper (Nunc). The resulting debris was removed by gentle washing
with medium. After that, cells were maintained for up to 12 h in standard culture medium with either
GP (0.5 to 1.0 mg/mL) or vehicle control in an incubator coupled to an Axio Observer D1 inverted
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microscope (Zeiss). The images of the closing wound were acquired by time-lapse microscopy at
30-min intervals and analyzed using the AxioVision Rel. 4.6.3 image analysis software (Zeiss). The data
were expressed as the percentage of regeneration in each time interval.
The wound scratch assay is a well-established method to study wound healing in vitro and is
thought to be particularly suited for measuring cell migration [44].
4.5.8. Measurement of Reactive Oxygen Species (ROS)
The generation of ROS by endothelial cells treated with the GP extract (0.5 to 1.0 mg/mL) was
assessed by labeling with 2′–7′-dichlorodihydrofluorescein diacetate (H2DCFDA) that is trapped inside
the cells and activated by intracellular ROS. Following the exposure to test solutions, 2 × 104 cells were
loaded with 10 µM H2DCFDA for 30 min and then treated with the lysis buffer. Fluorescence emitted
by cell lysates was measured in a Wallac Victor spectrofluorometer (Perkin-Elmer, Finland) using
wavelengths of 485 nm and 535 nm for excitation and emission, respectively. During the experiments of
ROS detection in vitro, the internal positive control (100 µM H2O2) was also detected. In addition, the
HUVEC line and EA.hy926 line were incubated ± GP extract (0.5–1.0 mg/mL) for 24 h in 6 well dishes.
Trypsinized cells (2.5–3 × 105) were washed twice in cold PBS and dihydrorhodamine 123 (10 µg/mL)
was added. After 30 min of incubation at 37 ◦C, the samples were measured by a BDFACS Aria
III cytometer and results were analyzed by FACS Diva Software. Dihydrorhodamine 123 (DHR)
infiltrates the cell membrane and, after oxidation by ROS, is converted to rhodamine 123, which emits
a green fluorescent signal after excitation by a blue laser (λ = 488 nm). ROS levels were measured
as the difference in median fluorescence intensity (MdFI). As a control, we used cells with correct
concentrations of GP extract without DHR.
4.5.9. Statistical Analysis
Statistical analysis was performed with an analysis of variance and post-hoc testing using
GraphPad Prism™ 6.00 software (Graph Pad Software Inc., San Diego, CA, USA). Results were
expressed as means ± SD. A p value of less than 0.05 was considered significant. The IC50 values were
calculated with Prism™ 6.0 software using nonlinear regression.
5. Conclusions
The anti-inflammatory activity of the rich polyphenol extract from GP herb is, at least in part,
related to free radical scavenging activity, inhibition of IL-6 release, and an inhibitory effect on
hyaluronidase activity. The results of this study demonstrate that such a plant extract could have
a potential as a drug in the treatment of skin disorders.
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